During his recovery, molecular testing on the biopsy reported a ROS1 fusion identified by fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) of tumor DNA identified a KRAS p.G12C mutation and a telomerase reverse transcriptase (TERT) promoter mutation (c.-124C>T). This evidence concerns the gene KRAS and neoplasm.